We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Idenix Pharmaceuticals has announced interim clinical trial data for valopicitabine
(NM283), the company's lead drug candidate for the treatment of hepatitis C.
Savient Pharmaceuticals has completed patient dosing in a Phase II clinical
trial of Puricase, a poly(ethylene glycol) (PEG) conjugate of recombinant porcine
uricase (urate oxidase), for the treatment of severe, refractory gout.
Genaera has announced positive preliminary clinical results, including improved
vision, from a multicenter open-label U.S. Phase II clinical trial (MSI-1256F-207)
with squalamine for the treatment of choroidal neovascularization associated
with age-related macular degeneration (AMD), also known as "wet" AMD.
Millennium Pharmaceuticals, in collaboration with Johnson & Johnson Pharmaceutical
Research & Development, has initiated VISTA (VELCADE as Initial Standard
Therapy in multiple myeloma: Assessment with melphalan and prednisone), a Phase
III clinical trial of VELCADE in combination with melphalan and prednisone versus
melphalan and prednisone in patients with newly diagnosed multiple myeloma who
are not transplant candidates.
Nabi Biopharmaceuticals has initiated its U.S. StaphVAX (Staphylococcus aureus
Polysaccharide Conjugate Vaccine) immunogenicity study in orthopedic surgery
patients with implanted devices.
ID Biomedical has received clearance from the FDA to begin immediate clinical
testing of its influenza vaccine, Fluviral, in the U.S. under an investigational
new drug (IND) application.
Elite Pharmaceuticals has announced that its subsidiary, Elite Laboratories,
has received promising results from a clinical program designed to test the
company's proprietary abuse resistant technology (ART) for narcotic analgesics,
such as OxyContin, utilizing naltrexone as a narcotic antagonist.